A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Summary

This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of life in afflicted individuals.

Timeline

Start

2022-10-20

Primary completion

2023-11-21

Completion

2023-11-21

Drugs

Indications